Use of phosphordiesterase inhibitors in the treatment of prostatic diseases

Abstract

The present invention pertains to the use of inhibitors of phosphodiesterase I, IV and V for the prophylaxis and treatment of prostatic diseases, in particular the use of a) 2-(2-propoxy-phenyl)-8-azapurin-6-one (zaprinast); b) dipyridamole; c) 1-(3-chlorophenylamino)-4-phenylphthalazine (M5445); d) 2-(N-(4-carboxypiperidine-6-chloro-4-(3,4-(methylendioxy)benzyl)amino)quinazoline (E 4021, ER 21355); e) 2,3-dihydro-8-hydroxy-7-nitro-1,4-benzodioxine-2-methanol, alpha-nitrate (E 4701); f) 4-((3,4-(methylendioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline; g) 1-methyl-3-propyl-6-(5-(N-(4-methylmorpholino)sulfonyl)-2-ethoxyphenyl)pyrazole[4,5]pyrimidin-4(5H)one (sildenafil); i) 1-cyclopentyl-3-methyl-6-(4-pyridinyl)pyrazolo (3,4-d)pyrimidin-4(5H)-one (WIN 58237); j) 7-(3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-2-hydroxy-propoxy)-2 -carboxy-2,3-didehydro-chronan-4-one (FPL-557212) k) quinazolines and their trimethoxy derivatives; l) Pyrazolopyrimidones; as well as pharmacologically compatible salts thereof, quinazolines and their trimethoxy derivatives, pyrazolopyrimidones or compatible salts thereof, in local and systemic administration

1 . Use of a component in the prophylaxis and treatment of prostatic diseases, in particular benign prostatic hyperplasia, the so-called urge symptoms, pollacuria (frequent micturition), nycturia (nocturnal micturition), weakened urine jet, urge incontinence (involuntary discharge of urine), prostatism, instabilities of the bladder muscles and impotence selected from the group of 
 a) 2-(2-propoxyphenyl)-8-azapurin-6-one (zaprinast);                          b) dipyridamole;                          c) 1-(3-chlorophanylamino)-4-phenylphthalazine (MY5445);                          d) 2-(N-(4-carboxypiperidine)-6-chloro-4-(3,4-(methylendioxy)benzyl)amino)quinazoline (E 4021, ER 21355);                          e) 2,3-dihydro-8-hydroxy-7-nitro-1,4-benzodioxine-2-methanol, alpha-nitrate (E 4701);    f) 4-((3,4-(methylendioxy)benzyl)amino)-6,7,6-trimethoxyquinazoline;                          g) 1-methyl-3-propyl-6-(5-(N-(4-methylmorpholino)sulfonyl)-2-ethoxyphenyl)pyrazole[4,5]pyrimidin-4(5H)one (Sildenafil);                          h) 2-n-butyl-5-chloro-1-(2-chlorobenzyl)4-methylacetateimidazole;                          i) 1-cyclopentyl-3-methyl-6-(4-pyridinyl)pyrazolo(3,4-d)pyrimidin-4-(5H)-one (WIN 58237);                          j) 7-(3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-2-hydroxypropoxy)-2-carboxy-2,3-didehydro-chronan-4-one (FPL-55712);                          k) quinazolines and their trimethoxy derivatives;    l) pyrazolopyrimidones;    as well as pharmacologically compatible salts thereof.    
     
     
         2 . Medicaments for the prophylaxis and treatment of prostatic diseases, in particular benign prostatic hyperplasia, the so-called urge symptoms, pollacuria (frequent micturition), nycturia (nocturnal micturition), weakened urine jet, urge incontinence (involuntary discharge of urine), prostatism, instabilities of the bladder muscles, and impotence, containing a component selected from the group of 
 a) 2-(2-propoxyphenyl-)8-azapurin-6-one (zaprinast);                          b) dipyridamole;                          c) 1-(3-chlorophenylamino)-4-phenylphthalazine (MY5445);                          d) 2-(N-(4-carboxypiperidine)-6-chloro-4-(3,4-(methylendioxy)benzyl)amino)quinazoline (E, 4021, ER 21355);                          e) 2,3-dihydro-8-hydroxy-7-nitro-1,4-benzodioxine-2-methanol, alpha-nitrate (E 4701);    f) 4-((3,4-(methylendioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline;                          g) 1-methyl-3-propyl-6-(5-(N-(4-methylmorpholino)sulfonyl)-2-ethoxyphenyl)pyrazole[4,5]pyrimidin-4 (5H)one (sildenafil);                          h) (2-n-butyl-5-chloro-1-(2-chlorobenzyl) 4-methylacetateimidazole;                          i) 1-cyclopentyl-3-methyl-6-(4-pyridinyl)pyrazolo(3,4-d)pyrimidin-4(5H)-one (WIN 58237);                          j) 7-(3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-2-hydroxypropoxy)-2-carboxy-2,3-didehydro-chronan-4-one (FPL-55712);                          k) quinazolines and their trimethoxy derivatives;    l) pyrazolopyrimidones;    as well as pharmacologically compatible salts thereof.    
     
     
         3 . Use of a component in the preparation of medicaments for the prophylaxis and treatment of prostatic diseases, in particular benign prostatic hyperplasia, the so-called urge symptoms, pollacuria (frequent micturition), nycturia (nocturnal micturition), weakened urine jet, urge incontinence (involuntary discharge of urine), prostatism, instabilities of the bladder muscles, and impotence, selected for the group of 
 a) 2-(2-propoxyphenyl-)8-azapurin-6-one (zaprinast);                          b) dipyridamole;                          c) 1-(3-chlorophenylamino)-4-phenylphthalazine (MY5445);                          d) 2-(N-(4-carboxypiperidine)-6-chloro-4-(3,4-(methylendioxy)benzyl)amino)quinazoline (E 4021, ER 21355);                          e) 2,3-dihydro-8-hydroxy-7-nitro-1,4-benzodioxine-2-methanol, alpha-nitrate (E 4701);    f) 4-((3,4-(methylendioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline;                          g) 1-methyl-3-propyl-6-(5-(N-(4-methylmorpholino)sulfonyl)-2-ethoxyphenyl)pyrazole[4,5]pyrimidin-4(5H)one (Sildenafil);                          h) (2-n-butyl-5-chloro-1-(2-chlorobenzyl)4-methylacetateimidazole;                          i) 1-cyclopentyl-3-methyl-6-(4-pyridinyl)pyrazolo(3,4-d)pyrimidin-4(5H)-one (WIN 58237);                          j) 7-(3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-2-hydroxypropoxy)-2-carboxy-2,3-didehydro-chronan-4-one (FPL-55712);                          k) quinazolines and their trimethoxy derivatives;    l) pyrazolopyrimidones;    as well as pharmacologically compatible salts thereof.